Advancements & Insights: Artificial Intelligence, New Treatments and Personal Experiences in the World of Multiple Sclerosis. MS News Roundup, July 24 - 30th

In this episode of The Just M.S. Show, we delve into the remarkable advances in the world of Multiple Sclerosis (MS) treatment and detection. From AI models predicting MS risk before symptoms appear to the groundbreaking addition of MS medications to WHO's Essential Medicines List, the hope for effective treatment is brighter than ever. We discuss the efficacy of ocrelizumab as a first-line treatment and the shift in disease-modifying therapy prescription towards oral medications. We also share personal stories of aging with MS, and the interplay between MS progression and normal aging processes. Finally, we explore fascinating research insights on how gut microbiome could trigger MS onset, and how Biogen's acquisition of Reata Pharmaceuticals might shape the future of rare disease treatments. Join us for these discussions and more as we navigate through the dynamic landscape of MS research, treatment, and personal experiences.

Intro – Justin kicks off the episode by introducing the listeners to the engaging content of the day which includes the latest breakthroughs in Multiple Sclerosis (MS) treatment, research, and personal experiences.

AI in Healthcare – Justin dives deep into a PRNewswire article highlighting the role of artificial intelligence (AI) and machine learning in predicting MS and minimizing laboratory errors.

https://www.prnewswire.com/news-releases/artificial-intelligence-models-predict-multiple-sclerosis-detect-contaminated-lab-samples-301883543.html

Essential Medicines Update – Discussion on the World Health Organization's new additions to the Model Lists of Essential Medicines for MS treatment, providing an analysis of how this could influence the lives of patients across the globe.

https://www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-decisions-on-essential-medicines-for-multiple-sclerosis

Ocrelizumab Efficacy – Detailed analysis of a Healio article revealing the effectiveness of ocrelizumab as a first-line treatment for MS, backed by a comprehensive 9-year research study.

https://www.healio.com/news/neurology/20230726/video-ocrelizumab-effective-as-firstline-treatment-for-ms

Aging with MS – In this heartfelt segment, Justin presents the narrative of Trevis Gleason from Everyday Health, where he shares his personal journey with aging and MS, which many listeners will relate to.

https://www.everydayhealth.com/columns/trevis-gleason-life-with-multiple-sclerosis/aging-with-ms/

Prescription Shifts – Delving into a study from HealthDay News, Justin discusses the noticeable shift towards oral disease-modifying therapies in MS treatment.

Gut Microbiome and MS – An exciting segment discussing research from Ludwig-Maximilians-Universität München about the relationship between the gut microbiome and the activation of auto-aggressive T cells in MS.

Biogen and Reata Acquisition – In the final part of the episode, Justin tackles Biogen's recent acquisition of Reata Pharmaceuticals, offering insights into how this might shape the future of the rare disease drugs market, including MS treatment.

https://www.washingtonpost.com/business/2023/07/28/biogen-deal-for-reata-signals-a-turn-to-rare-diseases/9cbf4a84-2d67-11ee-a948-a5b8a9b62d84_story.html

Outro – Wrapping up, Justin encourages the listeners to stay positive, informed, and connected, and invites them to join the next episode of "The Just M.S. Show".

Listeners are encouraged to refer to the episode description for link

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com